Bortezomib: An FDA approved drug

The FDA approved the Bortezomib drug for the treatment of patients with multiple myeloma and mantle cell lymphoma. Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine. The single-dose vials of Bortezomib come in 2 mg to administer intravenously and subcutaneously. The recommended starting dose of Bortezomib is 1.3 mg/m2. Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered. The common side-effects of Bortezomib are fever, numbness, tiredness, nausea, diarrhea, rash, abdominal pain, dehydration, and low white blood cells.
Bortezomib generic medicine is readily available with numerous suppliers of generic drugs. For further information, dial the toll-free no. 18008891064.
read more..